Search research articles
Contact Us
Filters
Showing results (421-430 of 523) with videos related to
Page
of 53
Sort By:
Journal of the American Academy of Dermatology
|
October 26, 2017
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Lluís Puig, Matthias Augustin, Andrew Blauvelt, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
February 5, 2020
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials
Alice B Gottlieb, Philip J Mease, Bruce Kirkham, et al.
Clinical Rheumatology
|
October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Philip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
The British Journal of Dermatology
|
September 12, 2015
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C Paul, J Cather, M Gooderham, et al.
JID Innovations : Skin Science From Molecules to Population Health
|
August 16, 2024
Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual Survey
Melissa P Zundell, Alexis R Ogdie-Beatty, Lourdes Perez-Chada, et al.
JAMA Dermatology
|
February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
Matthias Augustin, Steven R Feldman, Richard B Warren, et al.
International Journal of Dermatology
|
November 1, 2015
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis
Bruce Strober, Yang Zhao, Mary Helen Tran, et al.
Dermatology and Therapy
|
August 7, 2025
A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys
Lauren C S Kole, Yayoi Tada, Sascha Gerdes, et al.
The British Journal of Dermatology
|
June 5, 2015
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K Papp, D Thaçi, K Reich, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 18, 2013
Item-level psychometric properties for a new patient-reported psoriasis symptom diary
Bruce E Strober, Judit Nyirady, Usha G Mallya, et al.
Page
of 53
Search research articles
Search
Showing results (421-430 of 523) with videos related to
Sort By:
Page
of 53
Journal of the American Academy of Dermatology
|
October 26, 2017
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Lluís Puig, Matthias Augustin, Andrew Blauvelt, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
February 5, 2020
Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials
Alice B Gottlieb, Philip J Mease, Bruce Kirkham, et al.
Clinical Rheumatology
|
October 3, 2023
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment
Philip J Mease, Alice B Gottlieb, Alexis Ogdie, et al.
The British Journal of Dermatology
|
September 12, 2015
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C Paul, J Cather, M Gooderham, et al.
JID Innovations : Skin Science From Molecules to Population Health
|
August 16, 2024
Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual Survey
Melissa P Zundell, Alexis R Ogdie-Beatty, Lourdes Perez-Chada, et al.
JAMA Dermatology
|
February 18, 2026
Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension
Matthias Augustin, Steven R Feldman, Richard B Warren, et al.
International Journal of Dermatology
|
November 1, 2015
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis
Bruce Strober, Yang Zhao, Mary Helen Tran, et al.
Dermatology and Therapy
|
August 7, 2025
A Global Assessment of Patient Experience and Quality of Life in Generalized Pustular Psoriasis: Results from Interviews and Online Surveys
Lauren C S Kole, Yayoi Tada, Sascha Gerdes, et al.
The British Journal of Dermatology
|
June 5, 2015
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial
K Papp, D Thaçi, K Reich, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 18, 2013
Item-level psychometric properties for a new patient-reported psoriasis symptom diary
Bruce E Strober, Judit Nyirady, Usha G Mallya, et al.
Page
of 53